Published in Nature on July 08, 1999
Biomarker Study for Alzheimer's Disease (BiomarkerAD) | NCT02472899
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol (2008) 10.39
Pathways towards and away from Alzheimer's disease. Nature (2004) 8.72
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
Microglia in neurodegenerative disease. Nat Rev Neurol (2010) 5.83
The blood-brain barrier: bottleneck in brain drug development. NeuroRx (2005) 5.45
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 4.26
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
Endoplasmic reticulum stress in disease pathogenesis. Annu Rev Pathol (2008) 4.10
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov (2010) 3.48
Ageing and neuronal vulnerability. Nat Rev Neurosci (2006) 3.36
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A (2009) 2.96
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Role of toll-like receptor signalling in Abeta uptake and clearance. Brain (2006) 2.70
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med (2012) 2.66
Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A (2002) 2.62
Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov (2010) 2.58
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement (2009) 2.46
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med (2012) 2.38
Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci U S A (2012) 2.36
8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics (2007) 2.33
Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A (2003) 2.33
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med (2016) 2.31
The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation (2005) 2.23
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 2.23
The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) (2010) 2.21
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest (2004) 2.13
D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci U S A (2000) 2.11
The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol (2006) 2.10
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis (2008) 2.01
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc Natl Acad Sci U S A (2008) 1.99
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging (2007) 1.99
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets (2009) 1.94
Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol (2008) 1.93
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med (2008) 1.90
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci (2011) 1.86
The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med (2010) 1.86
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol (2014) 1.83
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Alzheimer's disease. Cold Spring Harb Perspect Biol (2011) 1.81
Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol (2010) 1.80
Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol (2004) 1.78
Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci (2008) 1.73
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J (2009) 1.73
Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2007) 1.73
Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience (2010) 1.70
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol (2001) 1.69
Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A (2002) 1.68
Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol (2004) 1.66
Dominant-negative inhibition of prion replication in transgenic mice. Proc Natl Acad Sci U S A (2002) 1.65
In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med (2004) 1.65
Alzheimer disease. Dis Mon (2010) 1.64
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest (2001) 1.63
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62
Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell (2007) 1.61
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx (2005) 1.58
Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther (2009) 1.57
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet (2014) 1.56
IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol (2010) 1.55
The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm (Vienna) (2006) 1.55
Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol (2000) 1.52
Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest (2002) 1.51
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron (2015) 1.49
Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol (2000) 1.49
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med (2008) 1.48
Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci U S A (2000) 1.47
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47
Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets (2011) 1.46
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
Alzheimer's disease. Antibody clears senile plaques. Nature (1999) 1.45
Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation (2005) 1.45
Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc Natl Acad Sci U S A (2006) 1.44
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res (2012) 1.41
The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol (2012) 1.41
Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 1.41
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40
Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng (2001) 20.65
Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science (1998) 19.40
The use of statins: a case of misleading priorities? BMJ (1997) 13.35
Nested retrotransposons in the intergenic regions of the maize genome. Science (1996) 12.95
Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA (2000) 10.91
Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res (2000) 10.78
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med (2001) 9.68
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol (1998) 7.41
Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature (1992) 7.16
Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75
Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol (1998) 5.48
TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity (1996) 5.45
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
Comparative genome mapping of Sorghum and maize. Genetics (1992) 5.14
A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature (1988) 5.11
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 4.92
Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science (1990) 4.71
Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis (1999) 4.67
Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis (1999) 4.59
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: A randomized controlled trial. JAMA (2001) 4.30
Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol (1992) 4.11
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci (1992) 4.10
Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst (2000) 4.09
Binding of myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol (1993) 4.08
An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. Cell (1999) 4.07
Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med (2011) 4.04
Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet (1983) 4.02
Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A (1988) 4.02
Appropriateness of the decision to transfer nursing facility residents to the hospital. J Am Geriatr Soc (2000) 3.99
The sounds from single motor units in a contracting muscle. J Physiol (1948) 3.75
APC-mediated proteolysis of Ase1 and the morphogenesis of the mitotic spindle. Science (1997) 3.73
How well does chart abstraction measure quality? A prospective comparison of standardized patients with the medical record. Am J Med (2000) 3.70
Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol (1997) 3.62
Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell (1999) 3.58
Cloned pigs produced by nuclear transfer from adult somatic cells. Nature (2000) 3.51
HIV and male circumcision--a systematic review with assessment of the quality of studies. Lancet Infect Dis (2005) 3.49
Virulence factors of Porphyromonas gingivalis. Periodontol 2000 (1999) 3.36
A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28
Effect of allelic heterogeneity on the power of the transmission disequilibrium test. Genet Epidemiol (2000) 3.24
Phospholipid:diacylglycerol acyltransferase: an enzyme that catalyzes the acyl-CoA-independent formation of triacylglycerol in yeast and plants. Proc Natl Acad Sci U S A (2000) 3.22
Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol (1998) 3.20
Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology (1999) 3.16
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia (2008) 3.04
Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene (2010) 3.04
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med (1997) 3.03
Characterization of the cell-wall polysaccharides of Arabidopsis thaliana leaves. Plant Physiol (1995) 3.03
Influence of PAX6 gene dosage on development: overexpression causes severe eye abnormalities. Cell (1996) 3.01
Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A (1998) 2.93
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci (1997) 2.91
Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science (1993) 2.89